MDMA-Assisted Psychotherapy: The Science Is What Matters
Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.
In this Mental Health Minute video, Ingmar Gorman, PhD, discusses his clinical research experience with MDMA-assisted psychotherapy. While disappointed about the US Food and Drug Administration's decision to issue a complete response letter for this treatment, he believes the science behind MDMA-assisted psychotherapy is what matters most. Participants encountered very difficult material during the treatment process, Gorman shares, but a majority saw clinical benefit.
Dr Gorman is a study therapist in the phase 3 clinical trial for MDMA-assisted therapy and a co-founder of Fluence, a psychedelic education company that trains mental health providers in psychedelic treatments.
